Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

30.91 +2.36 (+8.27%)
Streaming Delayed Price Updated: 11:34 AM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2
...
24 25 26 27 28 29 30 31 Next >
News headline image
3 Biotech Stocks to Turn $10,000 Into $1 Million: January 2024 ↗
Biotech stocks are some of the most exciting opportunities on the market. Find the right ones with catalysts, and you could make a fortune. 
Via InvestorPlace
News headline image
2 Stocks That Could Soar This Year: Are They Buys? ↗
They might perform well in 2024, but how will they do beyond that? 
Via The Motley Fool
News headline image
2 biotechs with promising weight-loss drugs coming
Clinical weight-loss medications have been making headlines as GLP-1 drugs like Novo Nordisk A/S (NYSE: NVO) owned Ozempic and Wegovy and Eli Lilly and Co. 
Via MarketBeat
News headline image
The 3 Best Biotech Stocks to Buy in January 2024 ↗
Biotech is still one of the most exciting investments on the market, creating substantial opportunities for some of the best biotech stocks. 
Via InvestorPlace
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
1 Under-the-Radar Stock That Could Triple By 2030 ↗
This small-cap biotech stock is going to compete against some giants. 
Via The Motley Fool
News headline image
Earnings Scheduled For October 25, 2023 ↗
Companies Reporting Before The Bell • Deutsche Bank (NYSE:DB) is estimated to report quarterly earnings at $0.52 per share on revenue of $7.65 billion. 
Via Benzinga
News headline image
2 Magnificient Growth Stocks I'm Buying in August ↗
These biotech stocks could markedly outperform the broader market. 
Via The Motley Fool
News headline image
M&A Watch: 3 Drug Maker Stocks That Could Be Acquired in 2024 ↗
Lower interest rates and the low valuation of many biotech stocks are likely to result in many drug maker stocks being acquired in 2024. 
Via InvestorPlace
News headline image
Better Growth Stock: Viking Therapeutics or Iovance Biotherapeutics? ↗
Both of these pharma stocks could be big winners. But one stock screens as a better buy from a risk standpoint. 
Via The Motley Fool
News headline image
Why Viking Therapeutics Was Crushing It This Week ↗
Nowadays, it's good to be a developer of next-generation weight loss drugs. 
Via The Motley Fool
News headline image
What's Going On With Viking Therapeutics Shares Tuesday? ↗
Viking Therapeutics Inc (NASDAQ: VKTX) shares are trading higher Tuesday after the company presented new data from its Phase 2b study 
Via Benzinga
Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders
EQNX::TICKER_START (NYSE:PTN),(NASDAQ:RYTM),(NASDAQ:VKTX),(NASDAQ:GPCR),(NYSE:NVO) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
9 Analysts Have This to Say About Viking Therapeutics ↗
 
Via Benzinga
News headline image
Why Are Stocks Down Today? ↗
Stocks are down again on Wednesday as investors continue to feel the effects of several major catalysts hitting the market. 
Via InvestorPlace
News headline image
Pfizer Layoffs 2023: What to Know About the Latest PFE Job Cuts ↗
Pfizer layoffs are a hot topic among PFE stock traders on Wednesday as they pour over the details of the job cuts amid a Covid slump. 
Via InvestorPlace
Topics Workforce
News headline image
Why Is Viking Therapeutics (VKTX) Stock Moving Today? ↗
Viking Therapeutics stock is on the move Wednesday as investors react to results from the company's latest clinical trial! 
Via InvestorPlace
News headline image
Why Talaris Therapeutics Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket ↗
Gainers Biocept, Inc. (NASDAQ: BIOC) shares surged 91.8% to $0.98 in pre-market trading after falling over 6% on Tuesday. Biocept recently filed for Chapter 7 bankruptcy in the U.S. Bankruptcy Court... 
Via Benzinga
Topics Bankruptcy
News headline image
Earnings Preview: Viking Therapeutics ↗
 
Via Benzinga
News headline image
Jim Carmer Is 'A Seller' Of This Company Because 'Elon Musk Said That He Doesn't Like That Business' ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Abbott Laboratories (NYSE: ABT) is a "very good company and will be up to the—let’s say—up to the challenge. I think that’s fair. 
Via Benzinga
News headline image
Consolidation In Viking Therapeutics Provides An Opportunity ↗
Viking Therapeutics Inc. (VKTX) is an innovative biotechnology company developing novel therapeutics for metabolic and endocrine diseases. 
Via Talk Markets
News headline image
Canopy Growth, DocGo And Other Big Stocks Moving Lower On Monday ↗
U.S. stocks traded mostly flat on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
3 Biotechs Compete for the Same $108-Billion-Dollar Market. Are They a Buy? ↗
NASH treatments are projected to be one of the most sought-after indications in the coming years. 
Via The Motley Fool
News headline image
Looking for the Next Big Biopharma Stock? These 4 Letters Are 1 Big Clue Where to Find It ↗
NASH is a surprisingly common ailment, and the first treatments are on the way. 
Via The Motley Fool
News headline image
The 7 Most Undervalued Healthcare Stocks to Buy Now: August 2023 ↗
All of these healthcare stocks to buy are underpriced and relatively stable investments over the mid-to-long term. 
Via InvestorPlace
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Are On Fire Today ↗
Novo Nordisk's popular weight loss drug also confers a significant cardioprotective effect, according to a new study. 
Via The Motley Fool
News headline image
Lilly Shares Up On Versanis Deal Amid Weight-Loss Drug Gold Rush
A bid to acquire Versanis boosts Eli Lilly & Co. by 2.80% in the past week, as the competition to develop the most effective weight-loss drug intensifies. 
Via MarketBeat
News headline image
3 Small-Cap Stocks That Could Be Big-Time Winners ↗
These stocks come with significant risks. But they could generate huge returns over time. 
Via The Motley Fool
News headline image
The Blazing Weight-Loss Drug Battle: Can Anyone Unseat Undisputed Leaders Novo Nordisk And Lilly? ↗
An overweight world is hungry for new treatments. For now, two companies own the market. 
Via Investor's Business Daily
< Previous 1 2
...
24 25 26 27 28 29 30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.